Cirazoline hydrochlorideCAS# 40600-13-3 |
- CFM 1571 hydrochloride
Catalog No.:BCC5924
CAS No.:1215548-30-3
- A 350619 hydrochloride
Catalog No.:BCC5939
CAS No.:1217201-17-6
- BAY 41-2272
Catalog No.:BCC7932
CAS No.:256376-24-6
- Riociguat
Catalog No.:BCC1899
CAS No.:625115-55-1
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 40600-13-3 | SDF | Download SDF |
PubChem ID | 11957512 | Appearance | Powder |
Formula | C13H17ClN2O | M.Wt | 252.74 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble to 100 mM in water and to 100 mM in DMSO | ||
Chemical Name | 2-[(2-cyclopropylphenoxy)methyl]-4,5-dihydro-1H-imidazole;hydrochloride | ||
SMILES | C1CC1C2=CC=CC=C2OCC3=NCCN3.Cl | ||
Standard InChIKey | XFRXWLWUUDJHPB-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C13H16N2O.ClH/c1-2-4-12(11(3-1)10-5-6-10)16-9-13-14-7-8-15-13;/h1-4,10H,5-9H2,(H,14,15);1H | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Selective α1 agonist. Also available as part of the α1-Adrenoceptor and Mixed Adrenergic. |
Cirazoline hydrochloride Dilution Calculator
Cirazoline hydrochloride Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 3.9566 mL | 19.7832 mL | 39.5664 mL | 79.1327 mL | 98.9159 mL |
5 mM | 0.7913 mL | 3.9566 mL | 7.9133 mL | 15.8265 mL | 19.7832 mL |
10 mM | 0.3957 mL | 1.9783 mL | 3.9566 mL | 7.9133 mL | 9.8916 mL |
50 mM | 0.0791 mL | 0.3957 mL | 0.7913 mL | 1.5827 mL | 1.9783 mL |
100 mM | 0.0396 mL | 0.1978 mL | 0.3957 mL | 0.7913 mL | 0.9892 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- C34
Catalog No.:BCC5603
CAS No.:40592-88-9
- GW3965 HCl
Catalog No.:BCC3790
CAS No.:405911-17-3
- GW3965
Catalog No.:BCC1612
CAS No.:405911-09-3
- SB590885
Catalog No.:BCC4392
CAS No.:405554-55-4
- Cyclapolin 9
Catalog No.:BCC7571
CAS No.:40533-25-3
- Dadahol A
Catalog No.:BCN5457
CAS No.:405281-76-7
- NFPS
Catalog No.:BCC7484
CAS No.:405225-21-0
- Dovitinib (TKI-258, CHIR-258)
Catalog No.:BCC1169
CAS No.:405169-16-6
- CHIR-124
Catalog No.:BCC3750
CAS No.:405168-58-3
- Besifloxacin HCl
Catalog No.:BCC4764
CAS No.:405165-61-9
- Drechslerine D
Catalog No.:BCN7502
CAS No.:405157-88-2
- Drechslerine A
Catalog No.:BCN7561
CAS No.:405157-84-8
- DMT-Cl
Catalog No.:BCC2799
CAS No.:40615-36-9
- DMT-T
Catalog No.:BCC2843
CAS No.:40615-39-2
- DSP-4
Catalog No.:BCC7527
CAS No.:40616-75-9
- ACHP
Catalog No.:BCC6223
CAS No.:406208-42-2
- IKK-2 inhibitor VIII
Catalog No.:BCC1642
CAS No.:406209-26-5
- Cornoside
Catalog No.:BCN7575
CAS No.:40661-45-8
- Taxifolin 3-O-beta-D-xylopyranoside
Catalog No.:BCN5458
CAS No.:40672-47-7
- O-Phospho-L-serine
Catalog No.:BCC6578
CAS No.:407-41-0
- Actinine
Catalog No.:BCN1744
CAS No.:407-64-7
- (-)-Bicuculline methiodide
Catalog No.:BCC7387
CAS No.:40709-69-1
- (+)-Nerolidol
Catalog No.:BCC8219
CAS No.:142-50-7
- CaCCinh-A01
Catalog No.:BCC6314
CAS No.:407587-33-1
Binding of [3H]cirazoline to an imidazoline site in rat brain and kidney membranes.[Pubmed:7589165]
Eur J Pharmacol. 1995 May 24;278(3):261-4.
Two classes of high-affinity sites for [3H]cirazoline were characterized in rat brain and kidney membranes. In both tissues, the binding parameters for the high- and low-affinity sites are similar with Bmax values of approximately 50 fmol/mg protein, Kd approximately 0.6 nM and Bmax approximately 470 fmol/mg protein, Kd approximately 11 nM respectively. Inhibition studies of [3H]cirazoline binding to the lower affinity site revealed that only guanidinium or imidazoline derivatives compete with the specific binding of this radioligand. Our results suggest that [3H]cirazoline could be used as a novel ligand to label the non-adrenergic imidazoline-preferring sites.
Further characterization of the guinea pig cerebral cortex idazoxan receptor: solubilization, distinction from the imidazole site, and demonstration of cirazoline as an idazoxan receptor-selective drug.[Pubmed:1972387]
J Neurochem. 1990 Jul;55(1):192-203.
We have demonstrated previously that [3H]idazoxan, besides being able to bind to alpha 2-adrenergic receptors, may also bind to a nonadrenergic idazoxan-receptor site with high affinity. The idazoxan receptor is tightly bound to cellular membranes, and we have now developed a method to solubilize it from the guinea pig cerebral cortex by using the detergent 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS). The CHAPS-solubilized receptor retains its binding properties for drugs: the membrane-bound, as well as the solubilized, idazoxan receptor shows high affinities for a number of imidazolines (cirazoline, idazoxan, tolazoline, naphazoline, tramazoline, clonidine, and oxymetazoline), some imidazoles (medetomidine, detomidine), and guanfacine. By contrast, catecholamines (adrenaline, noradrenaline, isoprenaline, and dopamine) and a number of other neurotransmitters and neuromodulators (serotonin, histamine, glutamic acid, gamma-aminobutyric acid, glycine, and adenosine) show negligible affinities for the idazoxan receptor. Moreover, the idazoxan receptor shows grossly different binding properties for histamine, cimetidine, and imidazole-4-acetic acid compared to what has been described for the nonadrenergic imidazole site labeled by p-[3H]amino-clonidine, indicating that the two receptor sites are distinct. Radioligand binding data further indicate that cirazoline is an idazoxan receptor-selective drug (KD = 1 nM) showing a 50-210-fold selectivity for binding to the idazoxan receptor when compared to alpha 2-adrenergic receptors and an about 500-fold selectivity when compared to alpha 1-adrenergic receptors. We have also reviewed the literature for possible nonadrenergic actions of idazoxan and cirazoline, and we suggest that idazoxan receptors might be involved in the control of prolactin release from the pituitary.
Renal effects of selective alpha-1 and alpha-2 adrenoceptor agonists in conscious, normotensive rats.[Pubmed:2882013]
J Pharmacol Exp Ther. 1987 Mar;240(3):723-8.
The effects of the selective alpha-1 adrenoceptor agonist, cirazoline, and the selective alpha-2 adrenoceptor agonist, B-HT 933, were assessed on renal hemodynamics and on water and solute excretion in conscious, chronically instrumented rats. Infusion (i.v.) of equipressor doses of cirazoline and B-HT 933, 0.04 and 4 mg/kg/hr, respectively, decreased renal plasma flow without changing glomerular filtration rate. Cirazoline infusion did not affect urinary excretion of water, electrolytes or total solutes. In marked contrast, B-HT 933 increased urine flow and sodium excretion significantly (P less than .01) but did not significantly alter potassium and urea excretion. Urine osmolality decreased to hyposmotic levels (from 613 +/- 86 to 172 +/- 8 mOsmol/kg of H2O) during the infusion of B-HT 933, suggesting a possible interaction between the alpha-2 adrenoceptor agonist and the vasopressin system. This diuretic action of the selective alpha-2 adrenoceptor agonist was also observed after the i.v. infusion of a subpressor dose (0.4 mg/kg/hr) of B-HT 933. In rats treated with the ganglionic blocker, hexamethonium (10 mg/kg i.v.), the B-HT 933-induced diuresis was not affected, confirming an action in the periphery, possibly at the level of the kidney. These results suggest that stimulation of renal alpha-2 adrenoceptors in conscious, euvolumic rats modulates the reabsorption of water and sodium at the site of the renal nephron.